M&T Bank
APGE icon

M&T Bank’s Apogee Therapeutics APGE Stock Holding History

M&T Bank’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$207K Buy
+1,560
New +$141K ﹤0.01% 1642

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

M&T Bank's APGE Position: Q2 2026 in Review

M&T Bank opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 1,560 shares worth $207K. The stake represents ﹤0.01% of the portfolio and ranks #1642 among its holdings.

288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • M&T Bank held 1,560 shares of Apogee Therapeutics worth $207K as of Q2 2026.
  • Apogee Therapeutics was a new M&T Bank position in Q2 2026.
  • Apogee Therapeutics made up ﹤0.01% of M&T Bank's portfolio in Q2 2026, its #1642 holding.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.